Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 306 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1998


1.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469

Last Modified: 6/1/2007 First Published: 10/1/1999


2.		Phase II/III Randomized Study of Leflunomide (SU101) With Mitoxantrone and Prednisone Versus Mitoxantrone and Prednisone Alone in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.035 SUGEN-990711, NCT00004071

Last Modified: 7/6/2007


3.		Phase II-III FAM (5-FU/ADR/MITO) vs V-FAM (FAM/VCR) vs Phase II Agent Chemotherapy for Advanced Gastric Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7841


4.		Phase II/III Comparison of VBL/Single-Dose DHAD vs VBL/5-Day DHAD for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				15 and over								MDA-MBDT-8085


5.		Phase III Chemotherapy with FAM-S(5-FU/ADR/MITO/SZC) vs Phase II Chemotherapy with Dihydroxyanthracenedione for Advanced Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 70				NCI				SWOG-8040/43 SWOG-8043


6.		Phase II/III Chemotherapy with ADR vs DHAD vs ADC for Breast Cancer Not Previously Exposed to Intercalating Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-8203/04 SWOG-8204

Last Modified: 4/10/2008


7.		Phase III Randomized Study of Induction and Intensification Regimens for Childhood Acute Myeloid Leukemia: IDA vs DNR with ARA-C/VP-16 for Induction in All Patients and Intensification with High-Dose ARA-C/DHAD (HAM) Before vs After Consolidation in High-Risk Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 17								GER-GPOH-AML-BFM-93 EU-93008

Last Modified: 6/1/1999


8.		Phase III Randomized Study of Mitoxantrone vs. Cyclophosphamide/Methotrexate/Fluorouracil (CMF) Chemotherapy for Good-Risk Metastatic Breast Cancer (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				35 to 80								GER-AIO-02/92 EU-93010

Last Modified: 5/3/2007 First Published: 1/1/1994


9.		Phase III Randomized Study of Mitoxantrone With or Without Docetaxel as First-Line Chemotherapy for Women With Poor Risk Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				80 and under				Other				GER-AIO-01/92 EU-93011, NCT00002544

Last Modified: 5/4/2007 First Published: 1/1/1994


10.		Phase III Randomized Study of Intensive Therapy for Acute Myelogenous Leukemia (the AML 10 Protocol): IDA vs DHAD vs DNR with ARA-C/VP-16 for Induction and Intermediate-Dose ARA-C for Consolidation Followed by AlBMT vs AuBMT vs PBSC (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 60								EORTC-06931 NCT00002549

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute